Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of […]readmore
Tags : Boehringer Ingelheim
Shots: PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform, SITESEEKER for the targets identified by BI and will be further […]readmore
Shots: The P-III study involves assessing BI 695501 vs Abbvie’s Humira in 147 patients with mod. to sev. CD that were either TNF naïve or prior treated with infliximab The […]readmore
Shots: The two P-III EMPERIAL-preserved & -reduced studies involve assessing the effect of 12wks. treatment of Jardiance (qd, 10mg) vs PBO in 315 & 312 patients with CHF along with […]readmore
1. Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune […]readmore
Shots: BI and Healx team up to discover new indications targeting rare neurological diseases by harnessing Healx’s AI-based drug discovery platform, Healnet to advance BI’s pipeline The collaboration combines BI’s […]readmore
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars […]readmore
Shots: Health Canada approved Ofev (nintedanib) as the first and only treatment, indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease […]readmore
Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: […]readmore
Shots: The US FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has voted (2 out of 14) against the use of Empagliflozin 2.5 mg as an add-on to insulin therapy in […]readmore